FlexCare Clinical Research, LLC (FlexCare) announced formation of the company, a clinical service provider focused on providing study visits in the home or alternate site settings via a network of clinicians.
FlexCare was created to meet demand from the biopharmaceutical industry to accelerate clinical trials and streamline study processes. Traditionally, clinical trials are conducted at investigative sites such as hospitals or clinics, where subjects are required to travel for protocol-related tests and assessments throughout the duration of the study. Consequently, for decades, subject recruitment and retention have become challenges in the timely completion of clinical trials. FlexCare’s service model is designed to take the study to the subject, where protocol activities can be conducted in their home or at other alternate locations. FlexCare’s services also hope to benefit pediatric or geriatric subjects, students and working adults who find participation in traditional studies inconvenient.
FlexCare centrally manages study visits that are conducted by its network of clinicians. Services offered by FlexCare include study drug administration, blood draws and other biologic sample collections, clinical assessments, questionnaires and training at the subject’s home or other convenient location.
With the company’s launch, Gail Adinamis was named to the role of chief executive officer. Concurrent with Adinamis’ appointment, Dr. Gizelle Baker was named chief operating officer and Dr. Debbie Wilkerson, chief scientific officer.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.